
During a live Twitter Spaces event hosted by Targeted Oncology, Naveen Pemmaraju, MD, explained key abstracts from ASH 2022 and how these data have influenced recent approvals in the hematology field.

During a live Twitter Spaces event hosted by Targeted Oncology, Naveen Pemmaraju, MD, explained key abstracts from ASH 2022 and how these data have influenced recent approvals in the hematology field.

The FDA has planned a regular review of the biologic license application for cosibelimab for the treatment for metastatic or locally advanced cutaneous squamous cell carcinoma.

JWATM214, an autologous T-cell immunotherapy candidate drug targeting GPC-3 for patients with advanced hepatocellular carcinoma, is now being investigated in a phase 1 trial.

In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.

YB-200, an investigational CEACAM antibody, has caught the attend of the FDA.

The phase 3 KEYNOTE-641 of pembrolizumab, enzalutamide, and androgen deprivation therapy has been discontinued, and overall survival rates in the phase KEYNOTE-789 study of pembrolizumab, pemetrexed, platinum-based chemotherapy did not meet statistical significance.

Looking at a subgroup analysis of patients with hormone receptor-positive and HER2-negative breast cancer on endocrine therapy, researchers saw promising results but worrying disparities between non-Hispanic White patients and non-Hispanic Black patients.

Data from the second interim analysis of the phase 3 MAGNITUDE study showed that the addition of niraparib to abiraterone acetate and prednisone prolonged survival for patients with metastatic castration-resistant prostate cancer with BRCA mutations.

With statistically significant and clinically meaningful event-free survival improvement in patients with stage II-IIIB Non–small cell lung cancer, could perioperative pembrolizumab in combination with chemotherapy become a new treatment option?

From the new approval for sacituzumab govitecan for a breast cancer subgroup to dostarlimab for dMMR advanced endometrial, February 2023 was an important month of FDA activity.

Charles Geyer, MD, discusses the potential impact of adjuvant olaparib on the treatment landscape for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

Retrospective research shows a link behind low household income and recurrence score and survival, but there is more to uncover behind the association between socioeconomic determinants of health and tumor biology.

In an interview with Targeted Oncology, Zahra Mahmoudjafari, PharmD, BCOP, discussed the post hoc analysis from the REACH2 trial and highlighted the key takeaways.

Jennifer R. Brown, MD, PhD, discusses what potential advancements are bringing excitement into the chronic lymphocytic leukemia space.

Efficacy findings from CheckMate-76 have led the FDA to accept the supplemental biologics license application and the EMA to validate the type II variation marketing authorization application for nivolumab alone in stage IIB or IIC melanoma.

Yann-Alexandre Vano, MD, explains the methods and design of the phase 2 BIONIKK trial for patients with renal cell carcinoma.

Zev A. Wainberg, MD, discusses recent findings from the NAPOLI 3 trial which were presented at the 2023 Gastrointestinal Cancers Symposium.

The phase 3 PhALLCON trial showed a trend toward event-free survival in patients with Philadelphia chromosome positive acute lymphoblastic leukemia when treated with ponatinib compared with imatinib.

Based on the FDA’s review of a new drug application, a phase 2 study will evaluate the safety and efficacy of azeliragon for patients with glioblastoma.

Data from the phase 3 DeFi trial showed that nirogacestat led to a 71% reduction in the risk of disease progression compared with placebo for adult patients with desmoid tumors. Now, the FDA has granted a priority review to the new drug application for nirogacestat.

The developer of avapritinib has announced full registrationL results from the phase 2 PIONEER study of avapritinib for the treatment of indolent systemic mastocytosis.

Discussing his presentation from the 2023 ASCO Genitourinary Symposium, Neal Shore, MD, FACS, looks at the long-term results of the phase 3 ARAMIS study for patients with nonmetastatic castration-resistant prostate cancer on darolutamide.

Experts addressed ARX788 for patients with HER2-positive breast cancer, and a data update from the update for APEX-01 evaluating ARX517 in patients with prostate cancer was provided during a virtual analyst and investor day.

Treatment with (Z)-endoxifen in combination with exemestane plus goserelin in the phase 2 EVANGELINE is now underway.

A phase 1 dose-escalation and -expansion clinical trial will evaluate BA3182, a potential anticancer therapy, for patients with advanced adenocarcinoma based on the clearance of an investigational new drug application from the FDA.

A read out from the phase 3 KEYNOTE-859 at the February ESMO Virtual Plenary hints pembrolizumab/chemotherapy is a new treatment choice for locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

In an interview with Targeted Oncology, Lori Muffly, MD, discusses the subanalysis of a phase 1 study of briquilimab plus low-dose total body radiation and fludarabine which was presented at 2023 Tandem Meetings on Transplantation and Cellular Therapy.

Research shows a high occurrence of ibrutinib-related cardiotoxicity in patients with cancer. This is the first study showing such evidence.

Matthew Ingham, MD, highlights a recent clinical study in the sarcoma space and discusses what else is being evaluated for this patient population.

The FDA has granted a breakthrough therapy designation to mRNA-4157/V940 based on data from KEYNOTE-942 which showed that the addition of an mRNA vaccine to adjuvant pembrolizumab improved recurrence-free survival following resection of high-risk melanoma.